CRO/CDMO performance remains subdued: Despite improving biopharma funding and R&D activity, macro uncertainty, uneven biotech financing, and longer development timelines continue to limit near-term upside.

CROs command the stronger valuation premium: CROs trade at roughly 19.7x revenue, supported by clinical-development demand, backlog visibility, and a more asset-light model.

CDMOs retain attractive but lower multiples: CDMOs trade near 15.7x revenue, with strong outsourcing demand offset by capacity utilization, capital intensity, and execution risk.

Outsourcing supports premium EBITDA valuations: CROs and CDMOs trade at about 4.3x and 3.9x EBITDA, respectively, versus 1.8x for broader healthcare, reflecting structural demand for outsourced development and manufacturing.

Complex modalities remain a key growth driver: Biologics, ADCs, and other advanced modalities should continue supporting demand for specialized CRO/CDMO capabilities and premium valuations.

Outsourcing remains the core structural growth driver: Pharma is increasingly externalizing both manufacturing and clinical-development functions to reduce fixed costs, access specialized expertise and accelerate development. CDMOs are increasingly moving toward integrated end-to-end / CRDMO models, while CROs benefit from continued clinical outsourcing penetration.

Complex modalities are creating premium niches: Growth in biologics, ADCs, peptides/GLP-1s, oligonucleotides and cell & gene therapies is increasing demand for technically sophisticated manufacturing capacity, while sterile fill-finish remains an important industry bottleneck.

CRO demand is improving, but funding translates into trials with a lag: Recovering biotech capital formation is supporting more RFP activity, while pharma’s upcoming patent cliff is driving pipeline replenishment through licensing, M&A and accelerated clinical development.

Technology is reshaping CRO economics: Decentralized trials, wearables, EHR integration, automated patient matching and AI are improving recruitment and trial execution. At the same time, AI could pressure traditional billable-service models and increase the strategic value of proprietary datasets and clinical technology platforms.

Capacity quality matters more than capacity alone: CDMO economics are highly sensitive to utilization because of substantial fixed costs. Specialized, well-utilized assets can generate attractive economics, whereas excess or poorly positioned capacity can significantly pressure margins.

Supply-chain localization is becoming strategic: Geopolitical risk, BIOSECURE-related concerns and supply-chain resilience are encouraging China+1 strategies, dual sourcing and U.S./European manufacturing expansion, potentially increasing the strategic value of established Western facilities.

M&A is increasingly a buy-vs-build decision: Given the time required to construct, validate and scale specialized facilities, strategics and PE sponsors are acquiring established manufacturing capacity, technical capabilities, patient-recruitment platforms and specialized CRO assets instead of building organically. The transaction pages show activity across both strategic and sponsor-backed buyers.

Valuations remain highly differentiated: The public-comps analysis shows median CDMO EV/LTM Revenue of ~3.1x and EV/LTM EBITDA of ~13x, versus approximately 2.1x revenue and 13x EBITDA for CROs. The wide company-level dispersion indicates investors are differentiating strongly based on growth, specialization, margins and asset quality rather than valuing the sectors uniformly.